This bill, HB 1772-FN-A, establishes a framework for the state's participation in a multistate consortium to conduct clinical trials using ibogaine as an investigational new drug for treating substance use disorders and various neurological or mental health conditions. It introduces a new chapter, Chapter 126-ZZ, which includes definitions, participation criteria, and reporting requirements, as well as the establishment of two dedicated funds: the ibogaine clinical research trial fund and the ibogaine intellectual property fund. The Department of Health and Human Services will administer a grant program to support these trials, with eligibility criteria for funding that includes a history of research in neurological diseases and a commitment to securing matching funds from non-state sources.

Additionally, the bill includes a $1 appropriation to the Department of Health and Human Services for the fiscal year ending June 30, 2027, to facilitate the state's involvement in the consortium, with the effective date for this appropriation set for July 1, 2026. The bill also outlines conditions under which ibogaine can be prescribed and administered, contingent upon FDA approval. While the bill does not specify any deletions from current law, it introduces new legal language to support the initiative, and the fiscal impact remains undetermined pending further financial insights from the Department of Health and Human Services.

Statutes affected:
Introduced: 6:12
HB1772 text: 6:12